Dana Flanders
Stock Analyst at Guggenheim
(0.10)
# 4,402
Out of 5,042 analysts
7
Total ratings
16.67%
Success rate
-19.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dana Flanders
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VALN Valneva SE | Maintains: Buy | $17 → $15 | $9.27 | +61.81% | 1 | Mar 24, 2025 | |
| SCYX SCYNEXIS | Initiates: Buy | $25 | $0.66 | +3,687.88% | 1 | Jan 22, 2021 | |
| PCRX Pacira BioSciences | Initiates: Neutral | n/a | $21.38 | - | 1 | May 27, 2020 | |
| HRTX Heron Therapeutics | Initiates: Buy | $24 | $1.16 | +1,968.97% | 1 | May 27, 2020 | |
| COLL Collegium Pharmaceutical | Initiates: Neutral | n/a | $36.00 | - | 1 | May 27, 2020 | |
| EBS Emergent BioSolutions | Upgrades: Buy | $60 → $75 | $12.48 | +500.96% | 2 | Nov 2, 2018 |
Valneva SE
Mar 24, 2025
Maintains: Buy
Price Target: $17 → $15
Current: $9.27
Upside: +61.81%
SCYNEXIS
Jan 22, 2021
Initiates: Buy
Price Target: $25
Current: $0.66
Upside: +3,687.88%
Pacira BioSciences
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $21.38
Upside: -
Heron Therapeutics
May 27, 2020
Initiates: Buy
Price Target: $24
Current: $1.16
Upside: +1,968.97%
Collegium Pharmaceutical
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $36.00
Upside: -
Emergent BioSolutions
Nov 2, 2018
Upgrades: Buy
Price Target: $60 → $75
Current: $12.48
Upside: +500.96%